Initial therapy for human immunodeficiency virus: Broadening the options

HIV Clinical Trials

Volumn 5, Issue 2, 2004, Pages 99-111

  Sension, Michael ^a  

^a North Broward Hospital District   (United States)

Author keywords

Antiretroviral; Human immunodeficiency virus; Initial therapy

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; INTEGRASE INHIBITOR; INTERLEUKIN 2; L 870812; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; NELFINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDEX EC; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIFE CYCLE; MEDICAL RESEARCH; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT FAILURE; VIRUS STRAIN;

AIDS VACCINES; ANTI-RETROVIRAL AGENTS; CARBAMATES; CLINICAL TRIALS; DEOXYCYTIDINE; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; OLIGOPEPTIDES; PHOSPHORIC ACID ESTERS; PYRIDINES; PYRONES; SULFONAMIDES;

EID: 2542615948     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/0H45-8QWU-FAUD-7E36     Document Type: Review

References (75)

1. Hogg RS, Rhone SA, Yip B, et al. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS. 1998;12:279-284.
2. Tashima KT, Hogan JW, Gardner LI, et al. A longitudinal analysis of hospitalization and emergency department use among human immunodeficiency virus-infected women reporting protease inhibitor use. Clin Infect Dis. 2001;33:2055-2060.
3. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
4. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS. 2000;14:1333-1339.
5. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS. 2003;17(suppl 1):S141-S148.
6. De Bethune MP, Andries K, Ludovici D, et al. TMC 120, a next generation NNRTI, has potent in vitro activity against NNRTI-resistant HIV variants [abstract 304]. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/ 304.htm. Accessed February 2, 2004.
7. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288:222-235.
8. Thaker HK, Snow MH. HIV viral suppression in the era of antiretroviral therapy. Postgrad Med J. 2003;79:36-42.
9. Package insert: Fuzeon™ (enfuvirtide) for injection. Available at: http://www.rocheusa.com/products/fuzeon/pi.pdf. Accessed February 4, 2004.
10. Package insert: Crixivan® (indinavir sulfate) capsules. Available at: http://www.crixivan.com/crixivan/shared/documents/pi.pdf. Accessed February 4, 2004.
11. Package insert: Invirase® (saquinar mesylate) tablets. Available at: http://www.rocheusa.com/products/invirase/pi.pdf. Accessed February 4, 2004.
12. Package insert: Viracept® (nelfinavir mesylate) tablets. Available at: http://www.viracept.com/brochures/PI.pdf. Accessed February 4, 2004.
13. Package insert: Fortovase® (saquinavir) capsules. Available at: http://www.rocheusa.com/products/fortovase/pi.pdf. Accessed February 4, 2004.
14. Package insert: Agenerase® (amprenavir) capsules. Available at: http://us.gsk.com/products/assets/us_agenerase_capsules.pdf. Accessed February 4, 2004.
15. Package insert: Norvir® (ritonavir capsules). Available at: http://www.norvir.com/pdf/norpi2a.PDF. Accessed February 4, 2004.
16. Kaletra™ (lopinavir/ritonavir) capsules (lopinavir/ritonavir) oral solution. Available at: http://www.rxabbott.com/PDF/kaletrapi.pdf. Accessed February 4, 2004.
17. Package insert: Reyataz® (atazanavir sulfate) capsules. Available at: http://www.bms.com/cgi-bin/anybin.pl?sql=select%20PPI%20from%20TB_ PRODUCT_PPI%20where%20PPI_SEQ=103. Accessed February 4, 2004.
18. Package insert: Lexiva™ (fosamprenavir calcium) tablets. Available at: http://us.gsk.com/products/assets/us_lexiva.pdf. Accessed December 1, 2003.
19. Package insert: Retrovir® (zidovudine) tablets. Available at: http://www.gsk.com/products/retrovir_us.htm. Accessed February 4, 2004.
20. Package insert: Videx® (didanosine). Available at: http://www.bms.com/cgi-bin/anybin.pl?sql=select%20PPI%20from%20TB_ PRODUCT_PPI%20where%20PPI_SEQ=21&key=PPI. Accessed February 4, 2004.
21. Package insert: Hivid® (zalcitabine) tablets. Available at: http://www.rocheusa.com/products/hivid/pi.pdf. Accessed February 4, 2004.
22. Package insert: Zerit® (stavudine) capsules and oral solution. Available at: http://www.bms.com/cgi-bin/anybin.pl?sql=select%20PPI%20from%20TB_ PRODUCT_PPI%20where%20PPI_SEQ=22&key=PPI. Accessed February 4, 2004.
23. Package insert: Epivir® tablets (lamivudine tablets). Available at: http://us.gsk.com/products/assets/us_epivir.pdf. Accessed February 4, 2004.
24. Package insert: Combivir® (lamivudine/zidovudine) tablets. Available at: http://us.gsk.com/products/assets/us_combivir.pdf. Accessed February 4, 2004.
25. Package insert: Ziagen® (abacavir sulfate) tablets. Available at: http://www.gsk.com/products/ziagen_us.htm. Accessed February 4, 2004.
26. Package insert: Trizivir® (abacavir sulfate, lamivudine, and zidovudine) tablets. Available at: http://us.gsk.com/products/assets/us_trizivir.pdf. Accessed February 4, 2004.
27. Package insert: Viread® (tenofovir disoproxil fumarate) tablets. Available at: http://www.viread.com/pi.pdf. Accessed February 4, 2004.
28. Package insert: Emtriva™ (emtricitabine) capsules. Available at: http://www.emtriva.com/fpi.pdf. Accessed February 4, 2004.
29. Package insert: Videx® EC (didanosine). Available at: http://www.bms.com/cgi-bin/anybin.pl?sql=select%20PPI%20from%20TB_ PRODUCT_PPI%20where%20PPI_SEQ=87&key=PPI. Accessed February 4, 2004.
30. Zerit® XR (stavudine). New drug application to the FDA. Available at: http://www.fda.gov/cder/foi/label/2002/21453_Zerit_lbl.pdf. Accessed February 4, 2004.
31. Package insert: Viramune® (nevirapine) tablets. Available at: http://www.bidocs.com/renetnt:/Prescribing+Information/Pls/ Viramune/Viramune.pdf. Accessed February 2, 2004.
32. Package insert: Rescriptor® (delavirdine mesylate) tablets. Available at: http://www.pfizer.com/download/uspi_rescriptor.pdf. Accessed February 2, 2004.
33. Package insert: Sustiva® (efavirenz) capsules and tablets. Available at: http://www.bms.com/cgi-bin/anybin.pl?sql=select%20PPI%0A%0 9%09%09%09%20%20%20from%20TB_PRODUCT_ PPI%20%0A%09%09%09%09%20%20%20where%20PPI_SEQ%20=%2094&key=PPI. Accessed February 4, 2004.
34. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569-571.
35. Sardana VV, Schlabach AJ, Graham P, et al. Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site. Biochemistry. 1994;33:2004-2010.
36. Soriano V, Gómez-Cano M, Bravo R, et al. Comparison of three different commercial methods for quantification of plasma HIV RNA in clinical specimens. Antivir Ther. 1997;2:119-120.
37. Yoshimura K, Kato R, Kavlick MF, et al. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J Virol. 2002;76:1349-1358.
38. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry: Nat Med. 1998;4:1302-1307.
39. De Clercq E. New anti-HIV agents and targets. Med Res Rev. 2002;22:531-565.
40. Goebel FD, Hemmer R, Schmit JC, et al. Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy. AIDS. 2001;15:33-45.
41. Levin J. Brand new drugs for HIV. Available at: http://www.natap.org/2002/HIVDrugRes/day1.htm. Accessed February 4, 2004.
42. Jacobson JM, Lowy I, Fletcher CV, et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis. 2000;182:326-329.
43. A study comparing 4 doses of S-1360 versus placebo in HIV-infected patients. Available at: http://clinicaltrials.gov/ct/show/NCT00046332?order=1. Accessed February 4, 2004.
44. De Clercq E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med Res Rev. 2000;20:323-349.
45. Reinke R, Lee DJ, Robinson WE Jr. Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo acid. Antimicrob Agents Chemother. 2002;46:3301-3303.
46. Druillennec S, Dong CZ, Escaich S, et al. A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity. Proc Natl Acad Sci USA. 1999;96:4886-4891.
47. Levin J. T-20 and T-1249. Available at: http://www.natap.org/2002/ICAAC/day10.htm. Accessed February 2, 2004.
48. Safety and effectiveness of zintevir (AR177) given to HIV-infected patients. Available at: http://clinicaltrials.gov/ct/show/nct00002403?order=1. Accessed August 15, 2003.
49. Levin J. New entry inhibitors in early development. Available at: http://www.natap.org/2002/ICAAC/day2.htm. Accessed February 4, 2004.
50. Levin J. HIV entry inhibitor: BMS=806. Available at: http://www.natap.org/2002/ICAAC/day28.htm. Accessed February 4, 2004.
51. Strain MC, Havlir D, Gunthard H, et al. Intrinsic decay rate of lymphocyte reservoirs of HIV-1 [poster 492-M]. Available at: http://63.126.3.84/2002/Abstract/13616.htm. Accessed February 4, 2004.
52. Pilcher CD. Entry inhibitors, the how and why of new agents at retrovirus: an update. Available at: http://www.natap.org/2003/Retro/day34.htm. Accessed February 4, 2004.
53. De Clercq E. Highlights in the development of new antiviral agents. Mini Rev Med Chem. 2002;2:163-175.
54. + lymphocyte level is better than HIV-1 plasma viral load in determining when to initiate HAART [abstract 519]. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/ 519.htm. Accessed February 4, 2004.
55. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-2577.
56. Chen R, Westfall A, Cloud G, et al. Long-term survival after initiation of antiretroviral therapy [abstract 341]. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/ 341.htm. Accessed February 4, 2004.
57. + lymphocyte count <200 cells/mL) is associated with increased risk of death [abstract 520]. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/ 520.htm. Accessed February 4, 2004.
58. 3: disease progression, treatment durability, and drug toxicity. Clin Infect Dis. 2003;36:812-815.
59. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [updated November 2003]. Available at: http://aidsinfo.nih.gov/guidelines/adult/AA_111003.pdf. Accessed November 14, 2003.
60. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother. 1997;41:654-660.
61. Bongiovanni M, Bini T, Tordato F, et al. Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study. J Antimicrob Chemother. 2003;51:171-174.
62. Nadler J, Gathe J, Pollard R, et al. Efficacy and safety of APV/RTV 600/100 mg BID compared to APV 1,200 mg BID. Available at: http://www.thebody.com/confs/aids2002/dejesus1.html. Accessed February 4, 2004.
63. Gerstoft J, Dragsted UB, Cahn P, et al. Final analysis of a randomized trial to evaluate safety and efficacy of indinavir/ritonavir versus saquinavir/ritonavir in adult HIV-1 infection: the MaxCmin1Trial [abstract H-172]. Presented at: 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, California; September 27-30, 2002. Abstracts Book. Herndon, VA: ASM Press; 263.
64. Moyle G. Boosted Pls: differences emerging in efficacy, tolerability, lipids. Available at: http://www.natap.org/2002/ICAAC/day26.htm. Accessed February 4, 2004.
65. Piliero P. The utility of inhibitory quotients in determining relative potency of protease inhibitors. AIDS. 2002;16:799-800.
66. O'Mara EM, Smith J, Olsen SJ, Tanner T, Schuster AE, Kaul S. BMS-232632: single and multiple oral dose safety and pharmacokinetic study in healthy volunteers [abstract 604]. Available at: http://www.retroconference.org/99/abstracts/604.htm. Accessed February 4, 2004.
67. O'Mara E, Mummaneni V, Randall D, et al. BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects [abstract 504]. Available at: http://www.retroconference.org/2000/abstracts/504.htm. Accessed February 4, 2004.
68. Colonno R, Rose R, Cianci C, Aldrovandi G, Parkin N, Friborg J. Emergence of atazanavir resistance and maintenance of susceptibility to other Pls is associated with an 150L substitution in HIV protease [abstract 597]. Available at: http://www.retroconference.org/2003/Abstract/Abstract.aspx?AbstractID= 1925. Accessed February 4, 2004.
69. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17:2603-2614.
70. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S, for the AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32:18-29.
71. Squires KE, Thiry A, Giordano M. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV+3TC: comparison of antiviral efficacy and safety through wk 24 (AI424-034) [abstract: H-1076]. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, CA, USA; September 27-30, 2002.
72. Murphy R, Pokrovsky V, Rozenbaum W, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-week results of BMS Study 008/044 [abstract and poster 555]. Available at: http://www.retroconference.org/2003/Abstract/Abstract.aspx?AbstractID= 2075. Accessed February 4, 2004.
73. Haas DW, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS. 2003;17:1339-1349.
74. Berger DS. FTC superiority over d4T in phase III trial. Posit Aware. 2002;13:48.
75. Cahn P, Raffi F, Saag M, et al. Virologic efficacy and patterns of resistance mutations in ART-naive patients receiving combination therapy with once-daily emtricitabine compared to twice-daily stavudine in a randomized, double-blind, multi-center clinical trial [abstract 433]. Available at: http://www.retroconference.org/2003/Abstract/Abstract.aspx?AbstractID=433